These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 7811540)

  • 41. Nevirapine: new drug, new class, new questions.
    Mascolini M
    J Int Assoc Physicians AIDS Care; 1996 Jul; 2(7):8-13. PubMed ID: 11363750
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Antiretroviral therapy. Current status and perspectives].
    Lüthy R
    Internist (Berl); 1994 Oct; 35(10):896-900. PubMed ID: 8002223
    [No Abstract]   [Full Text] [Related]  

  • 43. Virus sidesteps convergent therapy.
    GMHC Treat Issues; 1995 Jan; 9(1):6. PubMed ID: 11367380
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Alternating nevirapine and zidovudine treatment of human immunodeficiency virus type 1-infected persons does not prolong nevirapine activity.
    de Jong MD; Loewenthal M; Boucher CA; van der Ende I; Hall D; Schipper P; Imrie A; Weigel HM; Kauffmann RH; Koster R
    J Infect Dis; 1994 Jun; 169(6):1346-50. PubMed ID: 8195615
    [TBL] [Abstract][Full Text] [Related]  

  • 45. HIV phenotype switching during antiretroviral therapy: emergence of saquinavir-resistant strains with less cytopathogenicity.
    Ercoli L; Sarmati L; Nicastri E; Giannini G; Galluzzo C; Vella S; Andreoni M
    AIDS; 1997 Aug; 11(10):1211-7. PubMed ID: 9256938
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Resistance of human immunodeficiency virus type 1 to antiretroviral agents: a review.
    Erice A; Balfour HH
    Clin Infect Dis; 1994 Feb; 18(2):149-56. PubMed ID: 7512829
    [No Abstract]   [Full Text] [Related]  

  • 47. Zidovudine: five years later.
    McLeod GX; Hammer SM
    Ann Intern Med; 1992 Sep; 117(6):487-501. PubMed ID: 1503352
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Zidovudine resistance, syncytium-inducing phenotype, and HIV disease progression in a case-control study. The VA Cooperative Study Group.
    St Clair MH; Hartigan PM; Andrews JC; Vavro CL; Simberkoff MS; Hamilton JD
    J Acquir Immune Defic Syndr (1988); 1993 Aug; 6(8):891-7. PubMed ID: 8315574
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Failure of antiretroviral therapy: role of viral and cellular factors.
    Cinatl J; Cinatl J; Rabenau H; Doerr HW; Weber B
    Intervirology; 1994; 37(6):307-14. PubMed ID: 8586528
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pathogenicity and diversity of HIV and implications for clinical management: a review.
    Saag MS; Hammer SM; Lange JM
    J Acquir Immune Defic Syndr (1988); 1994; 7 Suppl 2():S2-10; discussion S10-1. PubMed ID: 7965648
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antiviral therapy in human immunodeficiency virus infections. Current status (Part I).
    Sandström E; Oberg B
    Drugs; 1993 Apr; 45(4):488-508. PubMed ID: 7684670
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Zidovudine. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.
    Wilde MI; Langtry HD
    Drugs; 1993 Sep; 46(3):515-578. PubMed ID: 7693435
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical significance of drug resistance in human immunodeficiency virus.
    Richman DD
    Clin Infect Dis; 1995 Oct; 21 Suppl 2():S166-9. PubMed ID: 8845446
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Issues in combination antiretroviral therapy: a review.
    Hammer SM; Kessler HA; Saag MS
    J Acquir Immune Defic Syndr (1988); 1994; 7 Suppl 2():S24-35; discussion S35-7. PubMed ID: 7965649
    [TBL] [Abstract][Full Text] [Related]  

  • 55. AIDS drugs. Harvard group makes a splash--twice.
    Cohen J
    Science; 1993 Aug; 261(5122):678. PubMed ID: 7688140
    [No Abstract]   [Full Text] [Related]  

  • 56. Prophylactic zalcitabine and interferon-alpha for a large-bore needlestick exposure to human immunodeficiency virus.
    Mildvan D; Bergé P; Starrett S; St Clair M; Salgo M
    J Acquir Immune Defic Syndr (1988); 1994 Apr; 7(4):416-7. PubMed ID: 8133452
    [No Abstract]   [Full Text] [Related]  

  • 57. Zidovudine therapy in HIV infection: which patients should be treated and when.
    Barry MG; Back DJ; Breckenridge AM
    Br J Clin Pharmacol; 1995 Aug; 40(2):107-10. PubMed ID: 8562291
    [No Abstract]   [Full Text] [Related]  

  • 58. Incidence of zidovudine-resistant human immunodeficiency virus isolated from patients before, during, and after therapy.
    Land S; McGavin C; Lucas R; Birch C
    J Infect Dis; 1992 Nov; 166(5):1139-42. PubMed ID: 1402026
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Correlation of clinical progression in human immunodeficiency virus-infected children with in vitro zidovudine resistance measured by a direct quantitative peripheral blood lymphocyte assay.
    Nielsen K; Wei LS; Sim MS; Deveikis A; Keller M; Stiehm ER; Frenkel LM; Bryson YJ
    J Infect Dis; 1995 Aug; 172(2):359-64. PubMed ID: 7622878
    [TBL] [Abstract][Full Text] [Related]  

  • 60. New HIV drugs cast in supporting roles.
    Voelker R
    JAMA; 1996 Aug; 276(8):585. PubMed ID: 8773618
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.